IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.885
AS - Asia 3.110
EU - Europa 2.595
SA - Sud America 381
AF - Africa 55
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 10
Totale 10.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.798
CN - Cina 1.890
SG - Singapore 599
IE - Irlanda 594
UA - Ucraina 412
FI - Finlandia 385
HK - Hong Kong 366
BR - Brasile 332
DE - Germania 274
RU - Federazione Russa 250
IT - Italia 199
SE - Svezia 168
GB - Regno Unito 148
VN - Vietnam 109
CA - Canada 51
FR - Francia 48
MX - Messico 27
IN - India 20
PL - Polonia 20
JP - Giappone 19
AR - Argentina 17
TR - Turchia 17
BE - Belgio 16
NL - Olanda 16
AT - Austria 14
IQ - Iraq 12
BD - Bangladesh 11
CZ - Repubblica Ceca 11
ES - Italia 11
ZA - Sudafrica 11
EC - Ecuador 10
EU - Europa 10
AU - Australia 9
SA - Arabia Saudita 9
MU - Mauritius 8
ID - Indonesia 7
CO - Colombia 6
KE - Kenya 6
LT - Lituania 6
RO - Romania 6
AZ - Azerbaigian 5
EG - Egitto 5
IL - Israele 5
NP - Nepal 5
PY - Paraguay 5
TN - Tunisia 5
CH - Svizzera 4
JO - Giordania 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
CR - Costa Rica 3
ET - Etiopia 3
LA - Repubblica Popolare Democratica del Laos 3
MA - Marocco 3
NG - Nigeria 3
PE - Perù 3
PK - Pakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
DK - Danimarca 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
MN - Mongolia 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
PT - Portogallo 2
BF - Burkina Faso 1
BG - Bulgaria 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GA - Gabon 1
GH - Ghana 1
GN - Guinea 1
HN - Honduras 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
MD - Moldavia 1
ML - Mali 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SO - Somalia 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.048
Salva come PNG Salva come JPEG
Città #
Chandler 692
Dublin 594
Jacksonville 522
Nanjing 459
Hong Kong 365
Ashburn 283
Beijing 263
Singapore 254
Dallas 224
Boardman 219
Nanchang 176
Princeton 136
Lawrence 131
Changsha 129
Wilmington 128
Hebei 116
Medford 109
Shenyang 107
Helsinki 102
Jiaxing 92
Los Angeles 89
New York 86
Tianjin 77
Buffalo 68
Hangzhou 68
Ann Arbor 67
Milan 50
Moscow 45
Pavia 44
Shanghai 44
Ho Chi Minh City 39
Munich 38
Toronto 34
Redondo Beach 33
Woodbridge 30
Turku 26
Norwalk 25
São Paulo 25
Hanoi 20
Warsaw 20
The Dalles 19
Tokyo 18
Guangzhou 17
Brussels 16
Falls Church 16
San Francisco 16
Seattle 16
Verona 16
Poplar 15
Santa Clara 15
Kunming 14
Washington 14
Brooklyn 13
Jinan 13
London 13
Belo Horizonte 12
Zhengzhou 12
Des Moines 11
Rome 11
Stockholm 11
Boston 10
Dearborn 10
Fairfield 10
Montreal 9
Nuremberg 9
Taizhou 9
Vienna 9
Atlanta 8
Chennai 8
Da Nang 8
Houston 8
Ningbo 8
Brasília 7
Chicago 7
Columbus 7
Denver 7
Falkenstein 7
Fuzhou 7
Haiphong 7
Orem 7
Ankara 6
Frankfurt am Main 6
Guarulhos 6
Hải Dương 6
Lanzhou 6
Nairobi 6
Porto Alegre 6
Baku 5
Johannesburg 5
Joinville 5
Mexico City 5
Olomouc 5
Tappahannock 5
Wuhan 5
Amman 4
Auburn Hills 4
Dhaka 4
Governador Valadares 4
Hefei 4
Istanbul 4
Totale 6.580
Salva come PNG Salva come JPEG
Nome #
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 129
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 127
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 123
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 123
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 122
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 121
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 118
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 118
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 114
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 112
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 112
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 112
Classification and prognostic evaluation of myelodysplastic syndromes 110
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 109
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 109
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 106
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 101
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 99
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 99
Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation. 98
Clinical and biological implications of driver mutations in myelodysplastic syndromes 98
Prognosis of secondary acute myeloid leukemia 97
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 96
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 96
Ultrastructural and functional differences between normal and tumor endothelial progenitor cells 96
CD34 and CD2 expression in acute promyelocytic leukemia. 96
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 95
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. 95
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia 93
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 92
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 89
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 88
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 88
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 87
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 87
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 87
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 86
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 86
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. 86
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 85
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 85
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 85
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 84
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 84
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 82
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome 81
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 81
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 80
Myelodysplastic syndromes and bone marrow microenvironment. 80
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 79
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 79
Dendritic cells in acute promyelocytic leukaemia. 78
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 78
Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study. 78
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 77
Role of the molecular staging and response in the management of follicular lymphoma patients 77
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 77
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 77
In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. 76
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 76
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 76
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 76
Simian virus 40 and lymphoproliferative disorder. 75
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. 74
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 74
Improving the prognostic assessment of myelodysplastic syndromes by understanding the biology of the disease 74
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 74
Splenectomy for treatment of immune thrombocytopenic purpura. 73
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 73
Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 72
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study 72
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 72
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 72
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 72
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 71
Risk factors for Gram-negative infections in neutropenic patients. 71
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 71
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 70
Myelodysplastic syndromes with bone marrow fibrosis. 70
The genetic basis of myelodysplasia and its clinical relevance 70
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 70
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 69
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 69
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 69
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 69
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 69
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. 68
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 68
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia 68
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 67
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 67
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? 67
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 67
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 67
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 66
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 66
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) 66
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 66
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 65
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 64
Totale 8.478
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.210
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.210
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021448 0 0 0 0 0 88 9 117 19 108 90 17
2021/2022651 9 0 21 12 36 20 10 30 39 28 85 361
2022/20231.815 178 102 19 194 201 192 2 129 727 13 34 24
2023/2024665 56 182 28 63 53 175 11 24 3 15 21 34
2024/20251.612 61 145 86 39 28 64 47 138 325 60 183 436
2025/20262.030 251 295 424 521 400 139 0 0 0 0 0 0
Totale 10.236